| Methods |
RCT.
Double‐masked.
Placebo controlled. |
| Participants |
62 participants with OHT (6% with PEX).
Fellow eye served as control.
40% of the participants were African American.
Inclusion criteria: IOP between 24 and 35 mmHg, difference in baseline IOP between right and left eyes less than or equal to 3 mmHg, age 40 years or greater, open angles.
Exclusion criteria: visual acuity below 20/50, previous intraocular surgery or laser, systemic medication that alters IOP |
| Interventions |
Timolol 0.25% or 0.5% twice daily.
Untreated control (contralateral eye). |
| Outcomes |
Incidence of reproducible glaucomatous visual field defect (Goldmann kinetic and static perimetry with Humphrey 30‐2 and Octopus 32).
Incidence of progressive optic disc cupping (stereophoto). |
| Notes |
Mean follow up 56.1 months.
19 drop‐outs: 5 systemic adverse events caused by timolol. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
